The renin-angiotensin system and cardiovascular disease

Blood Pressure, Supplement

Volumn 9, Issue 1, 2000, Pages 5-8

  Hollenberg, N K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Angiotensin II receptor blockers; Angiotensin II type 1 receptor; Angiotensin converting enzyme inhibitors; Candesartan; Cardiovascular disease; Hypertension; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; TREATMENT FAILURE; ANIMAL; DRUG ANTAGONISM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 0034566815     PISSN: 08038023     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Do we need angiotensin II antagonists to treat hypertensive patients?
2. The effects of antihypertensive treatment on vascular disease: Reappraisal of the evidence in 1994
3. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
4. Control and cardiovascular risk factors of hypertension. An assessment of a sample of patients
5. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population
6. Human chymase: Cellular localization and regional distribution of a major angiotensin-forming enzyme in the heart
7. Renin-angiotensin system inhibition: Which intervention site should be targeted?
8. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
9. Non-angiotensin effects of angiotensin converting enzyme inhibitors
10. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
11. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group
12. 1 receptor blockers in isolated vessels of different origin
13. 1 receptor
14. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled, forced titration study
15. Evaluation of clinical usefulness of TCV-116 (candesartan cilexetil) in patients with essential hypertension - A double-blind, parallel group comparison study using enalapril maleate as control drug
16. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect
17. Antihypertensive effects and tolerability of candesartan cilexetil, amlodipine and their combination
18. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension
19. Angiotensin receptors and their antagonists
20. Angiotensin II receptor inhibition
21. Molecular biology of angiotensin II receptors: An overview
22. Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II